New to The Street Announces its Five Business Guest Interviews, Episode 533, Airs on the FOX Business Network on Monday, November 27, 2023, at 10:30 PM PT
This is a paid press release. Contact the press release distributor directly with any inquiries.

New to The Street Announces its Five Business Guest Interviews, Episode 533, Airs on the FOX Business Network on Monday, November 27, 2023, at 10:30 PM PT

Trade ACVF on Coinbase
FMW Media Works Corp
FMW Media Works Corp

New to The Street Announces its Five Business Guest Interviews, Episode 533, which airs on the FOX Business Network on Monday, November 27, 2023, at 10:30 PM PT

Episode 533 will air the following five (5) business interviews: 1). Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ($ACXP) 2). Coastal Kapital, LLC. 3). American Conservative Values ETF (NYSE: ACVF) ($ACVF) 4). PetVivo Holdings, Inc. (NASDAQ: PETV) (NASDAQ: PETVW) ($PETV) 5). Sekur Private Data, Ltd. (OTCQX: SWISF) (CSE: SKUR) (FRA: GDT0) (Sekur®) - https://www.newtothestreet.com
Episode 533 will air the following five (5) business interviews: 1). Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ($ACXP) 2). Coastal Kapital, LLC. 3). American Conservative Values ETF (NYSE: ACVF) ($ACVF) 4). PetVivo Holdings, Inc. (NASDAQ: PETV) (NASDAQ: PETVW) ($PETV) 5). Sekur Private Data, Ltd. (OTCQX: SWISF) (CSE: SKUR) (FRA: GDT0) (Sekur®) - https://www.newtothestreet.com

NEW YORK, Nov. 24, 2023 (GLOBE NEWSWIRE) -- FMW Media's New to The Street announces its feature lineup for its business show airing on the FOX Business Network on Monday, November 27, 2023, at 10:30 PM PT.

New to The Street's TV episode 533 will air the following five (5) business interviews:

1). Biopharmaceutical - Acurx Pharmaceuticals, Inc.'s (NASDAQ: ACXP) ($ACXP) interview with David Luci, President/CEO.

2). Business Capital Firm - Coastal Kapital, LLC's interview with Kortney Murray, CEO/Founder.

3). ETF Fund - American Conservative Values ETF's (NYSE: ACVF) ($ACVF) interview with Bill Flaig, CEO/Founder.

4). Pet Health - PetVivo Holdings, Inc.'s (NASDAQ: PETV) (NASDAQ: PETVW) ($PETV) interview with John Lai, CEO/President.

5). "Sekur Privacy & Sekur Security – Weekly Hack Segment" interview with internet privacy expert Mr. Alain Ghiai, CEO, Sekur Private Data, Ltd. (OTCQX: SWISF) (CSE: SKUR) (FRA: GDT0) (Sekur®).

Episode 533

From the Nasdaq MarketSite Studio, New to The Street's TV Host Jane King talks with David Luci, the President/CEO of Acurx Phamaceuticals, Inc. (NASDAQ: ACXP) ($ACXP). As a clinical-stage biopharmaceutical business, ACXP is developing a new class of antibiotics for life-threatening bacterial infections. David updates viewers on the Company's FDA Phase 2 clinical trial on the Ibezapolstat drug, a treatment for patients with Clostridioides difficile Infections (CDI). Based on positive data from Phase 2a and Phase 2b, management is now going forward with the FDA Phase 3. The Company compared its top-line data with the currently used standard-of-care drugs in the marketplace, and Ibezapolstat has impressive positive results. Phases 2a and 2b confirmed that the drug had success in 25 out of 26 patients, approximately 96% success with no reinfections. Competitor drugs have been used for decades to treat CDI, but the reinfection rates are very high. ACXP's Ibezapolsat study results have shown to combat reinfections effectively. Based on the data and other publications regarding the market size for newly discovered and effective treatment of CDI, ACXP believes Ibezapolstat could be a market worth over $1B. David explains how the Company will fund its FDA Phase 3 study and, upon successful approval, will leverage data/results for future approval(s) with the European Medicines Agency. Decades-old antibacterial drugs are not working due to changes in the molecular composition of CDI. Thousands of people worldwide die annually, with many catching CDI in hospitals and nursing homes. Acurx Pharmaceuticals, Inc. believes its Ibezapolstat drug is the next generation for effectively treating CDI. The on-screen QR code is available during the show; download or visit Acurx Pharmaceticals, Inc. - https://www.acurxpharma.com/.